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Background: The Western Denmark Heart Registry (WDHR) has not previously been described 
as a research tool in clinical epidemiology.
Objectives: We examined the setting, organization, content, data quality, and research potential 
of the WDHR.
Method: We collected information from members of the WDHR organization, including the 
committee of representatives, the board, the data management group, and physicians reporting 
to the database. We retrieved 2008 data from the WDHR to illustrate database variables.
Results: The WDHR is a clinical database within a population-based health care system. It 
was launched on 1 January 1999 to monitor and improve the quality of cardiac intervention in 
Western Denmark (population: 3.3 million) and to allow for clinical and health-service research. 
More than 200,000 interventions, with 50–150 variables each, have been registered. The data 
quality is ensured by automatic validation rules at data entry combined with systematic validation 
procedures and random spot-checks after entry.
Conclusions: The WDHR is a valuable research tool because it provides ongoing longitudinal 
registration of detailed patient and procedural data. The Danish national health care system 
enables this research because it allows complete follow-up for medical events after cardiac 
intervention by linkage with multiple medical databases.
Keywords: cardiac surgical procedures, catheterization, coronary angiography, database, 
epidemiology, registries
Introduction
The Western Denmark Heart Registry (WDHR) is a clinical database within a 
population-based health care system. To improve cardiac treatment quality, the Danish 
National Board of Health decided in 1993 to increase the number of invasive cardiac 
interventions in Denmark.1 In response to this initiative, the WDHR was founded on 
January 1, 1999 as a collaborative effort by Western Denmark’s three major cardiac 
centers (Aarhus University Hospital-Skejby, Odense University Hospital, and Aarhus 
University Hospital-Aalborg) in order to monitor the cardiovascular treatment quality 
in Western Denmark. The remaining cardiac centers in Western Denmark (Varde Heart 
Centre, Region Hospital Viborg, Region Hospital Herning, Region Hospital Silkeborg, 
Vejle Hospital, Haderslev Hospital, Aarhus Hospital, Svendborg Hospital, and Hospital 
of Southwest Denmark-Esbjerg) joined the registry later. The participating centers own 
the WDHR and finance its operation through annual membership fees set according 
to hospital size.
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The WDHR serves as a regional data source to the Danish 
Heart Registry, which also contains data from Eastern Denmark 
and thus is responsible for the national monitoring of cardiac 
intervention quality.2,3 The WDHR, however, contains several 
data beyond what is delivered to the Danish Heart Registry.2,3 
Thus, in addition to monitoring and improving the cardiac 
intervention quality in Western Denmark, the aim of collecting 
data to the WDHR is to allow for clinical and health-service 
research on the use of and outcomes from these procedures. 
In this study we examined the setting, organization, content, 
data quality, and research potential of the WDHR.
Setting
Western Denmark has a population of 3.3 million (55% of 
the total Danish population; Figure 1). Denmark provides an 
optimal environment for conducting medical database-based 
research because: (i) the Danish National Health Service 
provides tax-supported universal health care, guaranteeing 
unfettered access to general practitioners and hospitals, and 
partial reimbursement for prescribed medications; (ii) cardiac 
intervention in Western Denmark are performed only at 
participating cardiac centers; (iii) all Danish citizens can be 
tracked in the health care system and national registries using 
the unique ten digit central personal registry (CPR) number 
assigned to each Danish citizen at birth and to residents upon 
immigration;4 and (iv) information on exposures, disease out-
comes, and potential confounding factors can be ascertained 
through CPR linkage to other Danish medical databases (Fig-
ure 2), which store information on eg, citizen vital statistics 
since 1968, including date of birth, change of address, date 
of emigration, and exact date of death (The Civil Registration 
System),5 specific causes of death since 1943 (The Registry 
of Causes of Deaths),6 characteristics of all nonpsychiatric 
inpatient admissions since 1977 and all outpatient clinic visits 
since 1995 (The National Patient Registry),7 prescribed medi-
cation since 1995 (The Nationwide Prescription Database),8 
and all laboratory results from patient blood samples since 
1997 (The Laboratory Database).9
Organization
The organization behind the WDHR comprises a committee 
of representatives, a board, and a data management group. The 
committee of representatives consists of medical specialists 
from the cardiac centers and includes nine cardiologists, 
three cardiac surgeons, and three anesthesiologists. One 
member from each specialty group is selected for the 
representatives’ executive committee with voting rights on 
the board. The committee of representatives coordinates 
all database changes, participates in securing data quality, 
reports to the Danish Heart Registry, and promotes future 
initiatives within the WDHR.
In addition to the representatives’ executive committee, 
the board consists of one hospital management representative 
from each of the three major cardiac centers, among whom 
the chairman is chosen. The board provides oversight, main-
tains contracts with database suppliers, sets annual member-
ship fees, defines the strategy and goals for the WDHR, and 
holds the responsibility for the budget and the data quality 
to the Danish Heart Registry.
The board appoints a data management group, which 
holds the responsibility for day-to-day management 
including implementing database changes, preparing annual 
reports, and daily communication between the committee of 
representatives, the board, and the database suppliers.
Study population
The WDHR includes all adult ($15 years) patients in 
Western Denmark referred for cardiac intervention, ie, 
invasive procedures (coronary angiography [CAG] or per-
cutaneous coronary intervention [PCI]), cardiac surgery 
(predominantly valve surgery and coronary artery bypass 
grafting [CABG]), and from 2008 also computed tomog-
raphy (CT) CAG.
Invasive CAG is performed at all cardiac centers like 
CT CAG, except at the Region Hospital Silkeborg, Aarhus 
Hospital, and Svendborg Hospital. PCI and cardiac surgery 
are performed only at the three major cardiac centers and 
the Varde Heart Centre. During 2008 more than 23,000 
procedures were performed.10 By January 2010, the WDHR 
contained patient data on approximately 120,000 CAGs, 
52,000 PCIs, 26,000 cardiac operations including 17,000 
CABGs, and 3,000 CT CAGs.10
Variables
The WDHR is derived from an internet-based online system, 
running on an encrypted public net. The board specifies the 
data profile. A common interface form secures standardized 
data collection from the cardiac centers. Data are entered 
by the physicians into a computer-based data manage-
ment system using the CPR numbers. Serial numbers for 
patients and procedures are automatically generated to 
protect patient confidentiality. There are no paper forms. 
An integrated help function helps to solve data registration 
problems. The concept of “one procedure – one interface” 
provides physicians with a visual overview of the variables 
to be filled in. Thus, for each procedure, physicians report Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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administrative data, including dates of referral, admission, 
operation, and discharge; and clinical data, including medi-
cal history, procedure data, lesion data, complications, and 
research study enrollments (Tables 1–3). Depending on the 
procedure type, 50 to 150 variables are registered for each 
procedure.
Treatment quality
Quantifiable variables have been selected as performance 
indicators for the quality of the health care efforts compared 
with prespecified standards set by the Danish Heart Registry 
(Table 3).11,12 The purpose of the performance indicators 
is to: assess the actual care given and its quality in order 
to detect care and service processes needing improvement 
(process indicators, [PI]); assess whether treatment outcomes 
meet a desired level (outcome indicators, [OI]); maintain 
and improve quality of care; and inform policy making 
or strategy at a regional and national level.12 The WDHR 
performance indicators are selected independently for the 
following interventions: CAG: adverse reaction to contrast 
fluid (OI, standard , 1%), arrhythmia during procedure 
(OI, standard , 1%), and bleeding complications from 
arterial puncture (OI, standard , 3%); PCI, in addition: 
acute CABG during   procedure (OI, standard , 0.5%), 
30-day mortality (OI, standard , 5%), and postinterven-
tion   secondary prophylaxis with clopidogrel and statins (PI, 
standard $ 95%); and cardiac surgery: 30-day mortality (OI, 
standard , 5%), central nervous lesion or acute myocardial 
infarction during hospitalization (OIs, standard , 5%), 
sternum infection (OI, standard , 3%), reintervention due 
to bleeding or within 6 months (OIs, standard , 10%), trans-
fusion (PI, standard yet to be defined), and postintervention 
secondary prophylaxis with statins (PI, standard $ 95%). 
Furthermore, improvements in the quality of care are also 
ascertained through ways other than performance indicators. 
As an example, the scope of surgery among patients aged 
80–90 years has been expanded to include complex surgery 
with both valve replacement and CABG. This expansion 
has been justified through surveillance of outcome data by 
means of the WDHR.
Data quality
Upgrades to the database platform have been performed in 
2003 and 2006. The next upgrade is scheduled for 2010. 
To improve data quality, it is mandatory to fill in more than 
two-thirds of the variables. The data quality is confirmed by 
automatic validation rules at data entry (eg, blood pressure 
levels are restricted within prespecified limits) combined with 
Figure 1 western Denmark area. western Denmark area includes (1) North Denmark Region, (2) Central Denmark Region, and (3) Region of Southern Denmark. Eastern 
Denmark area includes (4) Sealand Region and (5) Capital Region of Denmark.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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systematic validation procedures (through research projects 
and otherwise defined by the individual departments) and 
random spot checks after entry (through research projects 
and by the data management group). Data are entered by 
the physicians at the time of procedure and late procedure 
complications may, therefore, be incompletely recorded in the 
WDHR. For example, stent thrombosis may be incompletely 
registered unless the patient lives to receive revascularization 
treatment in connection with angiography. However, data 
linkage to national registries using the CPR numbers provides 
complete patient follow-up and ascertainment of late compli-
cations such as reinfarction, stroke, or cause of death.
The proportion of registrations completed (one minus 
the proportion of missing data) is monitored at two 
levels: (i) procedure registration through independent 
  ascertainment methods, in which the number of interventions 
registered in the WDHR is compared with that registered in 
the Danish National Patient Registry.13 In 2008 it was 98% 
for CAG, 98% for PCI, 97% for valve surgery, and 98% for 
CABG;10 (ii) variable registration through historic data methods, 
in which the number of registered variables for each interven-
tion is compared with the expected number calculated from the 
observed number of interventions.13 It is monitored and reported 
individually for the cardiac centers (Tables 1–3).
Research examples
WDHR data are well suited for studying predictors for 
multiple outcomes following cardiac intervention, such as 
Figure 2 Record linkage potential of Danish medical databases using the central personal registry (CPR) number.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Table 1 Examples of variables recorded for percutaneous coronary intervention in 2008. The proportion of completed variable 
registration is shown in table parentheses
Cardiac centersa Total  
(n = 5498) Skejby  
(n = 2273)
Odense  
(n = 1659)
Aalborg  
(n = 1164)
Varde  
(n = 402)
Medical history
Male gender, % 73 (100) 72 (100) 76 (100) 72 (100) 73 (100)
Age, years 65 (100) 64 (100) 64 (100) 64 (100) 65 (100)
ischemic heart disease in family, % 49 (98) 45 (54) 43 (75) 63 (97) 48 (80)
Smoking (current or former), % 79 (94) 78 (50) 81 (70) 75 (92) 79 (75)
Obesity (BMi $ 30), % 20 (96) 12 (45) 15 (65) 21 (82) 16 (73)
Diabetes mellitus, % 17 (99) 21 (55) 15 (76) 13 (97) 17 (81)
Lipid lowering therapy, % 62 (98) 65 (55) 55 (75) 83 (97) 63 (80)
Hypertension, % 51 (98) 51 (55) 53 (75) 59 (96) 52 (80)
Previous PCi, % 28 (99) 27 (55) 24 (76) 24 (97) 27 (81)
Previous myocardial infarction, % 26 (99) 23 (55) 27 (76) 27 (97) 26 (81)
Procedure data
PCi indication
  STEMi, % 26 (100) 35 (100) 29 (100) 2 (100) 27 (100)
  Non-STEMi or unstable angina, % 23 (100) 31 (100) 32 (100) 13 (100) 27 (100)
  Stable angina, % 42 (100) 30 (100) 35 (100) 79 (100) 40 (100)
  Other, % 9 (100) 4 (100) 4 (100) 6 (100) 6 (100)
Clinical presentationb
  Acute, % 31 (100) 39 (100) 32 (100) 2 (100) 31 (100)
  Subacute, % 30 (100) 32 (100) 32 (100) 25 (100) 31 (100)
  Elective, % 39 (100) 29 (100)  36 (100) 73 (100) 38 (100)
Target lesion revascularization
   Stent thrombosis, % 2 (100) 2 (100) 2 (100) 0.5 (100) 2 (100)
  in-stent restenosis, % 4 (100) 3 (100) 3 (100) 4 (100) 4 (100)
  Non-instent restenosis, % 1 (100) 0.6 (100) 1 (100) 1 (100) 1 (100)
Arterial access
  Femoral, % 96 (100) 99 (100) 89 (100) 100 (100) 96 (100)
  Radial or brachial, % 4 (100) 0.7 (100) 11 (100) 0.2 (100) 4 (100)
Procedure time, min 31 (100) 24 (99) 26 (98) 23 (100) 27 (99)
Fluoroscopy time, min 11 (100) 10 (100) 9 (100) 8 (100) 10 (100)
X-ray dose, Gy cm2 88 (100) 28 (100) 62 (100) 58 (100) 62 (100)
Contrast volume, ml 104 (100) 133 (100) 145 (100) 87 (100) 120 (100)
No. of treated lesions 1.3 (100) 1.3 (100) 1.3 (100) 1.4 (100) 1.3 (100)
No. of treated arteries, %
 0 1 (100) 2 (100) 2 (100) 1 (100) 2 (100)
 1 83 (100) 85 (100) 84 (100) 82 (100) 84 (100)
 2 14 (100) 13 (100) 13 (100) 16 (100) 14 (100)
 3 1 (100) 0.5 (100) 1 (100) 1 (100) 0.9 (100)
No. of balloons 1.8 (100) 1.5 (100) 1.6 (100) 1.5 (100) 1.6 (100)
No. of stents 1.4 (100) 1.3 (100) 1.5 (100) 1.3 (100) 1.4 (100)
Periprocedural antiplatelet therapy
  Acetylsalicylic acid, % 98 (100) 98 (100) 91 (100) 99 (100) 97 (100)
  Clopidogrel, % 92 (100) 97 (100) 85 (100) 97 (100) 92 (100)
  Glycoprotein iia/iiib antagonist, % 29 (100) 25 (100) 25 (100) 10 (100) 25 (100)
Lesion data
Lesion type,c %
 A 4 (95) 19 (94) 8 (91) 16 (95) 10 (94)
  B1 20 (95) 27 (94) 24 (91) 26 (95) 23 (94)
  B2 21 (95) 30 (94) 31 (91) 25 (95) 26 (94)
 C 55 (95) 24 (94) 37 (91) 33 (95) 40 (94)
Stenosis,d % of luminal diameter 93 (95) 90 (94) 90 (91) 86 (95) 91 (94)
Lesion length,d mm 24 (95) 20 (94) 21 (91) 19 (95) 22 (94)
Stent length,d sum in mm 27 (85) 25 (97) 26 (87) 23 (97) 26 (86)
Stent implantation ($1), % 90 (95) 93 (94) 95 (91) 92 (95) 92 (94)
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Table 1 (Continued)
Cardiac centersa Total  
(n = 5498) Skejby  
(n = 2273)
Odense  
(n = 1659)
Aalborg  
(n = 1164)
Varde  
(n = 402)
Stent type
  DES (with or without BMS), % 74 (100) 78 (100) 64 (100) 67 (100) 73 (100)
  BMS (without DES), % 11 (100) 8.7 (100) 23 (100) 20 (100) 13 (100)
Hospitalization time, days 1.5 (91) 2.3 (93) 2.1 (96) 1.1 (93) 1.8 (93)
Notes: values are means when % is not indicated.  aSkejby = Aarhus University Hospital-Skejby; Odense = Odense University Hospital; Aalborg = Aarhus University 
Hospital-Aalborg; varde = varde Heart Centre. bAcute (within hours): STEMi or cardiac arrest patients; Subacute (within days): patients with nonSTEMi, unstable angina, 
or crescendo angina; Elective (within weeks): patients (i) with stable angina, (ii) needing cardiac surgery, (iii) with systolic left ventricular failure, or (iv) with ventricular 
arrhythmias of unknown origin. cLesion classification with a distinction between simple B1 and complex B2 lesions: A = non-complicated, length ,10 mm; B = irregular, length 
10–20 mm; C = irregular, sidebranch, 90 degrees, chronic occlusion, length .20 mm.26,27 dBy visual estimate.
Abbreviations: BMi, body mass index; BMS, bare-metal stent; DES, drug-eluting stent; PCi, percutaneous coronary intervention; STEMi, ST-segment elevation myocardial 
infarction.
patient characteristics, comorbidity, medication use, and 
intra-interventional differences (eg, different types of stents 
or anesthesia). Furthermore, the WDHR is used as a platform 
for randomized controlled trials with clinical driven outcome 
detection.
In addition to the inherent variables in the WDHR, a 
committee of cardiac specialists has, owing to research 
purposes,14–18 added detailed information on stent throm-
bosis and cause of death. As defined by the Academic 
Research Consortium, the specialist committee adjudi-
cated the incidence of definite, probable, or possible stent 
thrombosis by retrieving medical records and reviewing 
catheterization angiograms. The committee also reviewed 
original paper death certificates ascertained from the 
National Registry of Causes of Deaths6 to classify death 
according to the underlying cause as cardiac or noncardiac 
death. Cardiac death was defined as an evident cardiac 
death, PCI-related death, unwitnessed death, and death 
from unknown causes. Thus, using these adjudicated 
outcomes from 12,395 patients undergoing PCI with 
stent implantation, Jensen et al14 concluded that the minor 
additional risk of stent thrombosis and myocardial infarc-
tion within 15 months after implantation of drug-eluting 
stents (DES) compared with bare-metal stents (BMS) 
was unlikely to outweigh the benefit of DES in reduc-
ing clinically necessary target lesion revascularization.14 
Table 2 Examples of variables recorded for cardiac surgery in 2008. The proportion of completed variable registration is shown in 
table parentheses
Cardiac centersa Total 
(n = 2389) Skejby 
(n = 963)
Odense 
(n = 527)
Aalborg 
(n = 435)
Varde 
(n = 464)
Procedure data
EuroSCORE 6 (95) 6 (100) 6 (97) 5 (100) 6 (97)
Logistic mortality,b % 11 (95) 8 (100) 9 (97) 5 (100) 9 (97)
Previous PCi, % 12 (85) 18 (100) 14 (84) 9 (100) 13 (91)
Operation, %
  CABG only 41 (100) 49 (100) 57 (100) 54 (100) 48 (100)
  valve surgery (0 $ CABG) 39 (100) 31 (100) 28 (100) 40 (100) 35 (100)
  Other 21 (100) 20 (100) 15 (100) 6 (100) 17 (100)
Time to procedure, days 54 (94) 30 (99) 30 (97) 19 (100) 37 (97)
Acute surgery, % 9 (95) 10 (100) 8 (97) 1 (100) 7 (97)
CABG On-Off-Pump, % 84 (82) 61 (100) 87 (82) 98 (100) 82 (90)
ECC time, min 98 (99) 125 (100) 110 (100) 60 (95) 97 (98)
Aortic clamp duration, min 60 (98) 83 (98) 68 (99) 38 (97) 61 (98)
Hospitalization time, days  14 (88) 11 (99) 10 (83) 7 (99) 11 (92)
Notes: values are means when % is not indicated. Other variables not presented include eg, medical history variables as shown in Table 1, number of peripheral 
anastomoses (1–6), cardioplegia direction (antegrade, retrograde, both, or non) and type (crystalloid solution, warm blood, or cold blood), and type of aortic or mitral 
valves (Carbomedics, Carpentier-Edwards, Medtronics, Mitroflow, Omnicarbon, St. Jude, Star, or plastic). aSkejby = Aarhus University Hospital-Skejby; Odense = Odense 
University Hospital; Aalborg = Aarhus University Hospital-Aalborg; varde = varde Heart Centre.  bThe EuroSCORE-predicted early mortality after cardiac surgery.28 
Abbreviations: CABG, coronary artery bypass grafting; ECC, extracorporeal circulation; EuroSCORE, European System for Cardiac Operative Risk Evaluation; PCi, 
percutaneous coronary intervention.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
143
western Denmark Heart Registry
The reduction in target lesion revascularization was also 
confirmed for ST-segment elevation myocardial infarction 
patients who were treated with primary PCI19 and for 
diabetic patients.20 Furthermore, comparing effectiveness 
of two types of DES –   sirolimus-eluting stents (SES) and 
paclitaxel-eluting stents (PES) – Maeng et al17 showed 
that PES increased the risk of target lesion revasculariza-
tion by 43% compared with SES.17 In addition, Kaltoft 
et al16 concluded that within two years of follow-up, PES 
increased the risk of stent thrombosis, myocardial infarc-
tion, and 1-year mortality compared with BMS and SES.16 
Cardiovascular outcomes have also been examined for 
other high risk patients with eg, spontaneous coronary 
artery dissection,21 or unprotected left main coronary artery 
stenosis treated with PCI.15
Obtaining information on all prescription medication 
through record linkage to the Nationwide Prescription 
Database makes the WDHR a valuable source for 
pharmacoepidemiological cardiovascular research. Use 
of nonselective NSAIDs and COX-2-selective enzyme 
inhibitors has been reported to increase cardiovascu-
lar risks in patients with coronary artery disease.22,23 
Schmidt et al18 examined whether this risk also related 
to patients undergoing coronary stent implantation, and 
found that overall there was no evidence to support such 
an association.18
In patients undergoing cardiac surgery, Jakobsen et al24 
investigated the cardioprotective effect of sevoflurane versus 
propofol anesthesia and found that sevoflurane seemed 
superior to propofol in patients with little or no ischemic 
heart disease, whereas propofol seemed superior in patients 
with severe ischemia, cardiovascular instability, or in acute 
or urgent surgery.24 In another study on drug effectiveness 
and safety during cardiac surgery, aprotinin treatment was 
found to increase the use of plasma and platelet transfusion 
and the risk for postoperative dialysis, but not other adverse 
outcomes, including short-term mortality.25
Conclusions
The WDHR is a valuable tool for clinical epidemiological 
research because it provides ongoing longitudinal 
registration of detailed patient and procedure data, which 
allows for research within invasive cardiology, cardiac 
surgery, anesthesia, and pharmacoepidemiology. The 
Danish national health care system enables this research 
because it allows complete follow-up for medical events 
after cardiac intervention by linkage with multiple medi-
cal databases.
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More information
The WDHR is administered according to Danish law. The 
data may be used in international collaborations at the 
discretion of the board and the participating cardiac centers. 
Additional information about the WDHR can be obtained 
through the corresponding author. Potential collaborators 
are invited to contact the board through Department of 
Cardiology, Aarhus University Hospital-Skejby.
Table 3 Performance indicators in 2008. The proportion of completed variable registration is shown in table parentheses
Performance indicators  
(standardsb)
Cardiac centersa Total
Skejby  Odense  Aalborg Varde 
PCI
Contrast fluid reactionc (,1), % 0.1 (100) 0.0 (100) 0.1 (100) 0.2 (100) 0.1 (100)
Arrhythmiac (,1), % 0.4 (100) 1.1 (100) 0.9 (100) 0.2 (100) 0.7 (100)
Arterial puncture bleeding (,3), % 0.7 (92) 3.5 (94) 0.9 (100) 0.3 (93) 1.5 (94)
Acute CABGc (,0.5), % 0.1 (100) 0.1 (100) 0.2 (100) 0.0 (100) 0.1 (100)
30-day mortality (,5), % 2.6 (99) 3.5 (99) 3.6 (99) 0.3 (96) 2.9 (99)
Cardiac surgery
Central nervous lesiond (,5), % 1.0 (97) 1.0 (100) 2.6 (87) 0.4 (99) 1.1 (96)
Acute myocardial infarctiond (,5), % 2.7 (85) 3.6 (99) 1.1 (87) 6.6 (98) 3.5 (91)
Sternum infectiond (,3), % 1.9 (97) 0.4 (100) 0.5 (87) 0.2 (99) 1.0 (96)
Reintervention due to bleeding (,10), % 7.3 (97) 6.1 (100) 4.7 (88) 5.5 (99) 6.2 (96)
Reintervention within 6 months (,10), % 5.2 (100) 3.6 (100) 6.7 (100) 1.9 (100) 4.5 (100)
30-day mortality (,5), % 2.8 (99) 5.9 (100) 3.7 (100) 1.1 (97) 3.3 (99)
Notes: aCardiac centers: Skejby = Aarhus University Hospital-Skejby; Odense = Odense University Hospital; Aalborg = Aarhus University Hospital-Aalborg; varde = varde 
Heart Centre. bTreatment standards set by the Danish Heart Registry; cDuring procedure; dDuring hospitalization.
Abbreviations: CABG, coronary artery bypass grafting; PCi, percutaneous coronary intervention.Clinical Epidemiology
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